Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
Almost all patients with multiple myeloma (MM) will eventually develop disease that has
relapsed with or become refractory to available treatments and will require additional …
relapsed with or become refractory to available treatments and will require additional …
3D-Shaped Binders of Unfolded Proteins Inducing Cancer Cell-Specific Endoplasmic Reticulum Stress In Vitro and In Vivo
The amount of unfolded proteins is increased in cancer cells, leading to endoplasmic
reticulum (ER) stress. Therefore, cancer cells are sensitive to drugs capable of further …
reticulum (ER) stress. Therefore, cancer cells are sensitive to drugs capable of further …
Targeted immunotherapy: harnessing the immune system to battle multiple myeloma
L Xu, C Wen, J Xia, H Zhang, Y Liang, X Xu - Cell Death Discovery, 2024 - nature.com
Multiple myeloma (MM) remains an incurable hematological malignancy disease
characterized by the progressive dysfunction of the patient's immune system. In this context …
characterized by the progressive dysfunction of the patient's immune system. In this context …
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
Background CD38 has been established as an important therapeutic target for multiple
myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and …
myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and …
Clinical pharmacokinetics and pharmacodynamics of daratumumab
Daratumumab is a fully human, monoclonal immunoglobulin G1 and a first-in-class CD38-
targeting drug approved by the US Food and Drug Administration for the treatment of …
targeting drug approved by the US Food and Drug Administration for the treatment of …
Management of relapsed–refractory multiple myeloma in the era of advanced therapies: evidence-based recommendations for routine clinical practice
Simple Summary Multiple myeloma is an incurable hematologic malignancy arising from
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …
Teclistamab‐cqyv in multiple myeloma
EA Martino, A Bruzzese, C Labanca… - European Journal of …, 2024 - Wiley Online Library
Multiple myeloma (MM) is an incurable neoplasm characterized by significant morbidity and
mortality. Despite advances in treatment, MM patients eventually experienced a relapse of …
mortality. Despite advances in treatment, MM patients eventually experienced a relapse of …
Immunotherapy approaches for hematological cancers
OL Lanier, E Pérez-Herrero, A PD'Andrea, K Bahrami… - Iscience, 2022 - cell.com
Hematological cancers such as leukemia, lymphoma, and multiple myeloma have
traditionally been treated with chemo and radiotherapy approaches. Introduction of …
traditionally been treated with chemo and radiotherapy approaches. Introduction of …
Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma
Multiple myeloma (MM) is a malignant plasma cell disorder accounting for around 1.8% of
all neoplastic diseases. Nowadays, clinicians have a broad arsenal of drugs at their disposal …
all neoplastic diseases. Nowadays, clinicians have a broad arsenal of drugs at their disposal …
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: the Mayo Clinic experience
POEMS (Polyneuropathy, Organomegaly, Endocrinopathies, Monoclonal protein, Skin
changes) syndrome is a rare paraneoplastic syndrome related to plasma cell disorders. The …
changes) syndrome is a rare paraneoplastic syndrome related to plasma cell disorders. The …